OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
Clinical trial sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics.... View Article
World first: a double forearm transplant thanks to marina lugworms from the company Hemarina
Amrita Institute of Medical Sciences (AIMS) in Kochi, India, Becomes the First Hospital in the World to Carry Out Bilateral... View Article
Healthcare sovereignty is closely linked to industrial recovery!
The key issue of the Plan France 2030 centres on restoring French sovereignty in certain strategic areas in order to... View Article
Valneva wins approval from European Commission to supply Covid-19 vaccines
Valneva, a specialty vaccine company and member of Atlanpole Biotherapies, announced that the European Commission (“EC”) has approved an agreement... View Article
New member | AGS-M
AGS-M is a young CDMO dedicated to the development, the optimization and validation of manufacturing processes (production, clarification, purification and... View Article
Valneva raises €88 million
Valneva, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new... View Article
Innovative medical device same™ by i-SEP : promising clinical results
MedTech – Autotransfusion or IntraOperative Cell Recovery Recovery of platelets in addition to red blood cells, a world premiere Following... View Article
KetoM+ is launching Cétoprane, a ketogenic medical food (DADFMS)
KetoM+, member of our network based in Le Mans, is launching Cétoprane, a ketogenic medical food (DADFMS) nutritionally adapted for... View Article
New member | Elisabeth Richard Business Development Consulting
Elisabeth Richard BD Consulting offers a business development (France and International) expertise in the fields of health and innovation having... View Article
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S) Neutralizing... View Article